Noxopharm OTC Stock Today

NOXOF -  USA Stock  

USD 0.39  0.00  0.00%

Noxopharm is trading at 0.39 as of the 25th of October 2021, a No Change since the beginning of the trading day. The stock's lowest day price was 0.39. Noxopharm has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Noxopharm are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 5th of November 2019 and ending today, the 25th of October 2021. Click here to learn more.
 Market Performance
0 of 100
  Odds Of Distress
Over 75
Noxopharm Limited, a drug development company, engages in the research and development of drugs for the treatment of cancer and prevention of septic shock in Australia and internationally. The company was incorporated in 2015 and is based in Chatswood, Australia. The company has 288.22 M outstanding shares. More on Noxopharm
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Noxopharm OTC Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Noxopharm's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Noxopharm or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Noxopharm generated a negative expected return over the last 90 days
Noxopharm has some characteristics of a very speculative penny stock
Noxopharm has high historical volatility and very poor performance
Noxopharm has high likelihood to experience some financial distress in the next 2 years
The company reported the revenue of 5.61 M. Net Loss for the year was (9.35 M) with profit before overhead, payroll, taxes, and interest of 5.61 M.
Noxopharm has accumulated about 26.8 M in cash with (8.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09.
Roughly 36.0% of the company outstanding shares are owned by corporate insiders
Latest headline from The ASX-listed biotech companies hoping to improve the lives of cancer patients - Proactive Investors Australia
Legal NameNoxopharm
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Noxopharm's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong SellOvervalued
Noxopharm [NOXOF] is traded as part of a regulated electronic over-the-counter service offered by the NASD. The company currently falls under 'Small-Cap' category with current market capitalization of 112.41 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Noxopharm's market, we take the total number of its shares issued and multiply it by Noxopharm's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Noxopharm classifies itself under Healthcare sector and is part of Biotechnology industry. The entity has 288.22 M outstanding shares. Noxopharm has accumulated about 26.8 M in cash with (8.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09.
Check Noxopharm Probability Of Bankruptcy
Noxopharm holds a total of 288.22 Million outstanding shares. Noxopharm holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation (%)

Check Noxopharm Ownership Details

Noxopharm Stock Price Odds Analysis

What are Noxopharm's target price odds to finish over the current price? Based on a normal probability distribution, the odds of Noxopharm jumping above the current price in 90 days from now is about 88.49%. The Noxopharm probability density function shows the probability of Noxopharm otc stock to fall within a particular range of prices over 90 days. Assuming the 90 days horizon Noxopharm has a beta of -0.4983. This indicates as returns on benchmark increase, returns on holding Noxopharm are expected to decrease at a much lower rate. During the bear market, however, Noxopharm is likely to outperform the market. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Noxopharm is significantly underperforming DOW.
 Odds Down 0.39HorizonTargetOdds Up 0.39 
11.46%90 days
Based on a normal probability distribution, the odds of Noxopharm to move above the current price in 90 days from now is about 88.49 (This Noxopharm probability density function shows the probability of Noxopharm OTC Stock to fall within a particular range of prices over 90 days) .

Noxopharm Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Noxopharm market risk premium is the additional return an investor will receive from holding Noxopharm long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Noxopharm. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Noxopharm's alpha and beta are two of the key measurements used to evaluate Noxopharm's performance over the market, the standard measures of volatility play an important role as well.

Noxopharm Stock Against Markets

Picking the right benchmark for Noxopharm otc stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Noxopharm otc stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Noxopharm is critical whether you are bullish or bearish towards Noxopharm at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Noxopharm without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Optimization Now


Portfolio Optimization

Compute new portfolio that will generate highest expected return given your specified tolerance for risk
All  Next Launch Module
Additionally, see Stocks Correlation. Note that the Noxopharm information on this page should be used as a complementary analysis to other Noxopharm's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Search module to search for activelly traded equities including funds and ETFs from over 30 global markets.

Complementary Tools for Noxopharm OTC Stock analysis

When running Noxopharm price analysis, check to measure Noxopharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Noxopharm is operating at the current time. Most of Noxopharm's value examination focuses on studying past and present price action to predict the probability of Noxopharm's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Noxopharm's price. Additionally, you may evaluate how the addition of Noxopharm to your portfolios can decrease your overall portfolio volatility.
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Is Noxopharm's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Noxopharm. If investors know Noxopharm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Noxopharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Noxopharm is measured differently than its book value, which is the value of Noxopharm that is recorded on the company's balance sheet. Investors also form their own opinion of Noxopharm's value that differs from its market value or its book value, called intrinsic value, which is Noxopharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Noxopharm's market value can be influenced by many factors that don't directly affect Noxopharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Noxopharm's value and its price as these two are different measures arrived at by different means. Investors typically determine Noxopharm value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Noxopharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.